Proteins such as GUSB, ALDH1A1, LPL, and IGFBPs warrant further investigation as potential biomarkers or therapeutic targets for MASLD prevention and treatment. This evidence concerns the gene LPL and metabolic dysfunction-associated steatotic liver disease.